Acute stroke reperfusion therapy trends in the expanded treatment window era

J Stroke Cerebrovasc Dis. 2014 Oct;23(9):2316-21. doi: 10.1016/j.jstrokecerebrovasdis.2014.04.023. Epub 2014 Aug 23.

Abstract

Background: The American Heart Association/American Stroke Association (AHA/ASA) recommended an expansion of the time window for acute ischemic stroke (AIS) reperfusion with intravenous (IV) recombinant tissue plasminogen activator (rt-PA) from 3 to 4.5 hours after symptom onset. We examine rates of IV and intra-arterial (IA) reperfusion before and after the recommendations to track guideline adoption in community practice.

Methods: Patients with AIS in the Paul Coverdell National Acute Stroke Registry spanning years 2007-2012 were identified. Trends in rates of IV rt-PA versus IA therapy were examined. Outcomes included symptomatic intracerebral hemorrhage (sICH), in-hospital mortality, ability to ambulate at discharge, and discharge destination.

Results: From 2007 to 2012, there were 182,235 AIS patients (median age, 72 years; 51.5% women) in the database at the time of analysis. AIS patients receiving IV rt-PA increased significantly from 3.7% in 2007 to 5.1% in 2012 in the ≤3 hours time window and from .2% in 2007 to 1.3% in 2012 in the 3-4.5 hours time window (P < .001 for both). There was also a significant increase in the rate of IA therapy between 2007 and 2012 (P < .001). There was a significant decrease in the rate of sICH among patients who received any reperfusion between 2007 and 2012.

Conclusions: There was a trend for increased utilization of IV rt-PA in the 0-3 hours and the 3-4.5 hours time windows, which began around the same time as the publication of AHA/ASA recommendations in 2009. This increase was associated with an increase in IA treatment rates along with a decrease in overall sICH rates for patients receiving any reperfusion.

Keywords: Expanded time window; ischemic stroke; thrombolysis—trend analysis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Guidelines as Topic
  • Hospital Mortality
  • Humans
  • Infusions, Intra-Arterial
  • Male
  • Middle Aged
  • Reperfusion / trends*
  • Socioeconomic Factors
  • Stroke / drug therapy
  • Stroke / mortality
  • Stroke / therapy*
  • Thrombolytic Therapy
  • Time-to-Treatment
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome
  • Young Adult

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator